Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | SLC18A2 | Q05940 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595038 | 1.00 | CYP2D6 (0.49) | CYP2D6CYP1A2HIF1ASLC18A2LMNA | |
| SCHEMBL6750129 | 0.87 | IDO1 (0.38) | CYP2D6CYP1A2HIF1ASLC18A2LMNA | |
| SCHEMBL6752552 | 0.87 | IDO1 (0.38) | CYP2D6CYP1A2HIF1ASLC18A2LMNA | |
| SCHEMBL4594526 | 0.86 | ALDH1A1 (0.35) | CYP2D6CYP1A2HIF1ASLC18A2LMNA | |
| SCHEMBL6186128 | 0.85 | CYP2D6 (0.42) | CYP2D6CYP1A2HIF1ASLC18A2LMNA | |
| SCHEMBL6186125 | 0.85 | CYP2D6 (0.42) | CYP2D6CYP1A2HIF1ASLC18A2LMNA | |
| SCHEMBL21995575 | 0.80 | — | — | |
| SCHEMBL1067641 | 0.80 | — | — | |
| SCHEMBL1067441 | 0.80 | — | — | |
| SCHEMBL4595234 | 0.80 | CYP2D6 (0.33) | CYP2D6CYP1A2SLC18A2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572655-A2 | NOVEL ARYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| WO-2002090332-A2 | NOVEL AEYLHETEROALKYLAMINΕ DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | CYP2D6 48/4885CYP1A2 11/4885HIF1A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.